$2.6T
Total marketcap
$169.2B
Total volume
BTC 49.99%     ETH 15.81%
Dominance

TG Therapeutics TGTX Stock

15.05 USD {{ price }} -1.116952% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
2.32B USD
LOW - HIGH [24H]
14.51 - 15.29 USD
VOLUME [24H]
2.67M USD
{{ volume }}
P/E Ratio
167.22
Earnings per share
0.09 USD

TG Therapeutics Price Chart

TG Therapeutics TGTX Financial and Trading Overview

TG Therapeutics stock price 15.05 USD
Previous Close 27.18 USD
Open 26.93 USD
Bid 0 USD x 3100
Ask 0 USD x 800
Day's Range 26.36 - 26.97 USD
52 Week Range 3.7 - 35.67 USD
Volume 2.35M USD
Avg. Volume 4.22M USD
Market Cap 3.96B USD
Beta (5Y Monthly) 2.09014
PE Ratio (TTM) N/A
EPS (TTM) 0.09 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 30.06 USD

TGTX Valuation Measures

Enterprise Value 3.74B USD
Trailing P/E N/A
Forward P/E -88.26666
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 461.50327
Price/Book (mrq) 133.73737
Enterprise Value/Revenue 436.758
Enterprise Value/EBITDA -23.016

Trading Information

TG Therapeutics Stock Price History

Beta (5Y Monthly) 2.09014
52-Week Change 555.44%
S&P500 52-Week Change 20.43%
52 Week High 35.67 USD
52 Week Low 3.7 USD
50-Day Moving Average 26.57 USD
200-Day Moving Average 14.56 USD

TGTX Share Statistics

Avg. Volume (3 month) 4.22M USD
Avg. Daily Volume (10-Days) 3.39M USD
Shares Outstanding 149.4M
Float 120.18M
Short Ratio 4.79
% Held by Insiders 8.85%
% Held by Institutions 72.16%
Shares Short 22.43M
Short % of Float 18.54%
Short % of Shares Outstanding 15.01%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 100:5625

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -1901.061%
Gross Margin 89.67%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -40.70%
Return on Equity (ttm) -170.41%

Income Statement

Revenue (ttm) 8.57M USD
Revenue Per Share (ttm) 0.06 USD
Quarterly Revenue Growth (yoy) 287.10%
Gross Profit (ttm) 2.52M USD
EBITDA -162664000 USD
Net Income Avi to Common (ttm) -168554000 USD
Diluted EPS (ttm) -1.22
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 139.71M USD
Total Cash Per Share (mrq) 1.01 USD
Total Debt (mrq) 108.43M USD
Total Debt/Equity (mrq) 395.26 USD
Current Ratio (mrq) 2.93
Book Value Per Share (mrq) 0.198

Cash Flow Statement

Operating Cash Flow (ttm) -167383008 USD
Levered Free Cash Flow (ttm) -109912248 USD

Profile of TG Therapeutics

Country United States
State NC
City Morrisville
Address 3020 Carrington Mill Blvd.
ZIP 27560
Phone 212 554 4484
Website https://www.tgtherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 237

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Q&A For TG Therapeutics Stock

What is a current TGTX stock price?

TG Therapeutics TGTX stock price today per share is 15.05 USD.

How to purchase TG Therapeutics stock?

You can buy TGTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for TG Therapeutics?

The stock symbol or ticker of TG Therapeutics is TGTX.

Which industry does the TG Therapeutics company belong to?

The TG Therapeutics industry is Biotechnology.

How many shares does TG Therapeutics have in circulation?

The max supply of TG Therapeutics shares is 154.42M.

What is TG Therapeutics Price to Earnings Ratio (PE Ratio)?

TG Therapeutics PE Ratio is 167.22221000 now.

What was TG Therapeutics earnings per share over the trailing 12 months (TTM)?

TG Therapeutics EPS is 0.09 USD over the trailing 12 months.

Which sector does the TG Therapeutics company belong to?

The TG Therapeutics sector is Healthcare.

TG Therapeutics TGTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Capital Market Composite RCMP 116.84 USD
-0.68
116.47 USD 117.72 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD